(Q36222023)

12 August 2017

1 reference

title

Treatment of dyslipidaemia in HIV-infected persons (English)

1 reference

12 August 2017

1 reference

Oriol Manuel

1

0 references

0 references

4

Philip E Tarr

1 reference

12 August 2017

Rodolphe Thiébaut

2

1 reference

12 August 2017

Roger Darioli

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

10

1 reference

12 August 2017

page(s)

1619-1645

1 reference

Adverse effects of antiretroviral therapy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Arterial stiffness and endothelial dysfunction in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Managing cardiovascular risk in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Switching effective antiretroviral therapy: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Pharmacotherapy for dyslipidaemia – current therapies and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Drug interactions in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Statins inhibit HIV-1 infection by down-regulating Rho activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Safety and statin therapy: reconsidering the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.10.1619

10.1517/14656566.6.10.1619

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference